Key facts
- 52-week range (closes)
- $43.30 – $72.61 Lowest close May 15, 2026, highest Sep 25, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- June Fiscal 2026 ended Jun 30, 2026, from SEC filings
- In the S&P 500 since
- Aug 30, 2021, replacing Maxim Integrated (MXIM) · Analog Devices acquired Maxim Integrated Products. · All S&P 500 changes
Bio-Techne (TECH) is trading up at $72.58 (+0.12%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Bio-Techne revenue & net income history (FY2017–FY2026)
| FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | FY2026Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $563.0M | $643.0M | $714.0M | $738.7M | $931.0M | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Growth (year over year) | +12.8% | +14.2% | +11.0% | +3.5% | +26.0% | +18.7% | +2.8% | +2.0% | +5.2% | −0.4% |
| Gross profit | $374.5M | $432.1M | $473.5M | $483.2M | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M | $799.1M |
| Gross margin | 66.5% | 67.2% | 66.3% | 65.4% | 68.0% | 68.4% | 67.7% | 66.4% | 64.8% | 65.8% |
| Operating income | $120.6M | $136.2M | $146.7M | $157.4M | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M | $251.9M |
| Operating margin | 21.4% | 21.2% | 20.5% | 21.3% | 25.5% | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net income | $76.1M | $126.2M | $96.1M | $229.3M | $140.4M | $272.1M | $285.3M | $168.1M | $73.4M | $181.8M |
| Net margin | 13.5% | 19.6% | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
| EPS (diluted) | $0.51 | $0.83 | $0.62 | $1.46 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Balance sheet | ||||||||||
| Cash and equivalents | $91.6M | $122.0M | $100.9M | $146.6M | $199.1M | $172.6M | $180.6M | $151.8M | $162.2M | $264.7M |
| Total assets | $1.56B | $1.59B | $1.88B | $2.03B | $2.26B | $2.29B | $2.64B | $2.70B | $2.56B | $2.59B |
| Total liabilities | $608.6M | $514.1M | $718.8M | $646.4M | $691.7M | $593.8M | $672.2M | $635.0M | $639.1M | $478.5M |
| Long-term debt | $343.8M | $339.0M | $492.7M | $344.2M | $328.8M | $243.4M | $350.0M | $319.0M | $346.0M | $200.0M |
| Shareholders' equity | $949.6M | $1.08B | $1.17B | $1.38B | $1.56B | $1.70B | $1.97B | $2.07B | $1.92B | $2.11B |
| Cash flow | ||||||||||
| Operating cash flow | $143.7M | $170.4M | $181.6M | $205.2M | $352.2M | $325.3M | $254.4M | $299.0M | $287.6M | $292.1M |
| Capital expenditure | $15.2M | $20.9M | $25.4M | $51.7M | $44.3M | $44.9M | $38.2M | $62.9M | $31.0M | $28.9M |
| Free cash flow | $128.5M | $149.4M | $156.2M | $153.5M | $307.9M | $280.4M | $216.1M | $236.1M | $256.6M | $263.2M |
| Dividends paid | $47.3M | $48.0M | $48.4M | $48.9M | $49.6M | $50.2M | $50.3M | $50.4M | $50.4M | $49.9M |
| Share buybacks | — | $0 | $15.4M | $50.1M | $43.2M | $160.9M | $19.6M | $80.0M | $275.7M | $41.7M |
| Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q3 FY26Mar 2026 | Q4 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $289.5M | $297.0M | $316.2M | $317.0M | $286.6M | $295.9M | $311.4M | $321.2M |
| Growth (year over year) | +4.5% | +9.0% | +4.2% | +3.5% | −1.0% | −0.4% | −1.5% | +1.3% |
| Gross profit | $183.0M | $193.9M | $214.6M | $198.8M | $188.1M | $191.3M | $208.3M | $211.4M |
| Gross margin | 63.2% | 65.3% | 67.9% | 62.7% | 65.6% | 64.6% | 66.9% | 65.8% |
| Operating income | $40.0M | $47.4M | $38.7M | −$23.9M | $47.7M | $54.5M | $75.5M | $74.3M |
| Operating margin | 13.8% | 16.0% | 12.2% | −7.5% | 16.6% | 18.4% | 24.2% | 23.1% |
| Net income | $33.6M | $34.9M | $22.6M | −$17.7M | $38.2M | $38.0M | $51.0M | $54.6M |
| Net margin | 11.6% | 11.7% | 7.1% | −5.6% | 13.3% | 12.8% | 16.4% | 17.0% |
| EPS (diluted) | $0.21 | $0.22 | $0.14 | −$0.11 | $0.24 | $0.24 | $0.32 | $0.36 |
| Balance sheet | ||||||||
| Cash and equivalents | $187.5M | $177.5M | $140.7M | $162.2M | $145.0M | $172.9M | $209.8M | $264.7M |
| Total assets | $2.74B | $2.67B | $2.64B | $2.56B | $2.53B | $2.52B | $2.55B | $2.59B |
| Total liabilities | $597.4M | $591.9M | $626.2M | $639.1M | $560.3M | $511.7M | $465.3M | $478.5M |
| Long-term debt | $300.0M | $300.0M | $330.0M | $346.0M | $300.0M | $260.0M | $200.0M | $200.0M |
| Shareholders' equity | $2.14B | $2.08B | $2.02B | $1.92B | $1.97B | $2.01B | $2.09B | $2.11B |
| Cash flow | ||||||||
| Operating cash flow | $63.9M | $84.3M | $41.1M | $98.2M | $27.6M | $82.4M | $86.7M | $95.4M |
| Capital expenditure | $9.17M | $6.82M | $10.1M | $4.89M | $5.36M | $5.92M | $9.09M | $8.48M |
| Free cash flow | $54.7M | $77.5M | $31.0M | $93.3M | $22.2M | $76.5M | $77.6M | $86.9M |
| Dividends paid | $12.7M | $12.7M | $12.6M | $12.4M | $12.4M | $12.5M | $12.5M | $12.5M |
| Share buybacks | — | — | $100.0M | $100.1M | $24.0K | $0 | $0 | $41.7M |
From Bio-Techne's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Bio-Techne vs the Health Care sector and the S&P 500
Bio-Techne's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Bio-Techne | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | −0.4% | +7.2% | +7.0% |
| Net margin, latest fiscal year | 15.0% | 12.9% | 12.9% |
| Dividend per share, latest fiscal year | $0.32 | $2.48 | $2.40 |
| Share price change, 1 year | +16.1% | +22.8% | +7.5% |
Bio-Techne: fiscal year ended June 2026, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Bio-Techne included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.
About Bio-Techne
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Source: Wikipedia — Bio-Techne
- Headquarters
- Minneapolis, Minnesota From SEC filings, Oct 2026
Recent News (20)
-
Americans likely to associate tech CEOs, even fake ones, with GOP: Poll Americans are more likely to assume the executives heading up the largest technology firms are Republican, marking a drastic shift in perception of what was once known as a liberal Silicon Valley, acc…
-
Musk endorses Paxton in Texas Senate race Tech mogul Elon Musk has formally endorsed Republican Ken Paxton in the Texas Senate race after bankrolling his campaign for several weeks. The tech billionaire and one-time trillionaire has spent mor…
-
Prediction: This Forgotten Tech Stock Could Make a Comeback by 2028 Prediction: This Forgotten Tech Stock Could Make a Comeback by 2028 AOL.com
-
Prediction: This Forgotten Tech Stock Could Make a Comeback by 2028 - 24/7 Wall St. Prediction: This Forgotten Tech Stock Could Make a Comeback by 2028 24/7 Wall St.
-
-
Top 3 Tech Stocks That May Keep You Up At Night This Month Top 3 Tech Stocks That May Keep You Up At Night This Month Benzinga
-
China’s tech giants drop $35 billion on export-compliant Nvidia RTX Pro 5500 workstation GPU orders to power AI ambitions, according to reports China’s tech giants drop $35 billion on export-compliant Nvidia RTX Pro 5500 workstation GPU orders to power AI ambitions, according to reports Yahoo Finance
-
Nasdaq futures slip as Korea tumble weighs on tech (SPX:) Nasdaq futures slip as Korea tumble weighs on tech (SPX:) Seeking Alpha
-
-
-
-
-
-
-
-
-
-
Robot factories and hypersonic missiles: JPMorgan Chase's first $5 billion of defense investments With $5 billion already deployed off its balance sheet, JPMorgan Chase is racing ahead on direct investments in defense tech, hardware and supply chains.
-
-
Microsoft pulls out of UK's largest AI data centre
Tech firm Nscale says it is still committed to building the site in Essex.
More Health Care stocks
- RVTY Revvity
- SOLV Solventum
- STE Steris
- SYK Stryker Corporation
- TMO Thermo Fisher Scientific
- UHS Universal Health Services
- UNH UnitedHealth Group
- VEEV Veeva Systems